Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS⢠technology platform allows us to identify immunotherapy targets based on each personâs tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude so-called âinhibitoryâ antigens that appear to exert an immunosuppressive effect on the patient. We are advancing complementary programs built from ATLAS insights: GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. Source
No articles found.
Neopenda is a medical device startup creating solutions that give patients in low-...
Neopenda is a medical device startup creating s...
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to im...
Five Prime Therapeutics, Inc. discovers and dev...
Castle Biosciences is a skin cancer diagnostics company focused on providing physi...
Castle Biosciences is a skin cancer diagnostics...
Acacia Diversified Holdings, Inc., is an emerging hemp company, through its wholly...
Acacia Diversified Holdings, Inc., is an emergi...
An emerging leader in the specialty pharmaceuticals industry, ANI Pharmaceuticals ...
An emerging leader in the specialty pharmaceuti...
Intrommune Therapeutics is a New York City-based biopharmaceutical company develop...
Intrommune Therapeutics is a New York City-base...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
Join the National Investor Network and get the latest information with your interests in mind.